Neurotech Device Sector Shows Growth, But Challenges Await
This article was originally published in The Gray Sheet
Participants at the recent Neurotech Investing and Partnering Conference are generally optimistic about the commercial potential for neurotechnology.
You may also be interested in...
Neurological devices panel votes in favor of device intended to reduce epileptic seizures despite lingering questions about the trial results.
As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.
Damage limitation action is expected imminently to try and stem the flow of medtech products being taken off the EU market. And it cannot come quickly enough as evidence continues to mount of the negative fall-out resulting from the way the EU’s new medical device regulations have been, and are being, implemented.